Monte Rosa Therapeutics (GLUE) Income from Continuing Operations (2023 - 2025)
Historic Income from Continuing Operations for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to -$27.1 million.
- Monte Rosa Therapeutics' Income from Continuing Operations fell 1350.43% to -$27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 million, marking a year-over-year increase of 11751.67%. This contributed to the annual value of -$72.7 million for FY2024, which is 4626.6% up from last year.
- Monte Rosa Therapeutics' Income from Continuing Operations amounted to -$27.1 million in Q3 2025, which was down 1350.43% from -$12.3 million recorded in Q2 2025.
- Monte Rosa Therapeutics' 5-year Income from Continuing Operations high stood at $46.9 million for Q1 2025, and its period low was -$35.2 million during Q2 2023.
- Its 3-year average for Income from Continuing Operations is -$18.2 million, with a median of -$30.3 million in 2024.
- Within the past 5 years, the most significant YoY rise in Monte Rosa Therapeutics' Income from Continuing Operations was 24658.43% (2025), while the steepest drop was 1350.43% (2025).
- Monte Rosa Therapeutics' Income from Continuing Operations (Quarter) stood at -$33.3 million in 2023, then surged by 140.32% to $13.4 million in 2024, then tumbled by 301.99% to -$27.1 million in 2025.
- Its last three reported values are -$27.1 million in Q3 2025, -$12.3 million for Q2 2025, and $46.9 million during Q1 2025.